Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China | Business Wire
THE FACES OF BREAST CANCER
Puma Biotech Expands Pierre Fabre License to Add Countries
Puma regains China rights to Nerlynx and amends deal with Fabre
Fight against cancer : our therapeutic responses | Pierre Fabre
Puma Bio: A Contrarian Investment That Requires Patience (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology, Pierre Fabre enter into Exclusive License Agreement
Pierre Fabre étend sa collaboration avec Puma Biotechnology
Puma and CANBridge cancel licensing deal for $20m
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
Fight against cancer : our therapeutic responses | Pierre Fabre
Pierre Fabre & NERLYNX commercialisation | Nerlynx
Puma regains China rights to Nerlynx and amends deal with Fabre
Blue March: Pierre Fabre supports colorectal cancer awareness month
Puma licences breast cancer therapy Nerlynx to Pierre Fabre in Europe
Pierre Fabre engagements | NERLYNX
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in
CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies | Pierre Fabre Pharma Norden AB
CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration | Business Wire
Fight against cancer : our therapeutic responses | Pierre Fabre
Disappointing Nerlynx sales shows Pierre Fabre timing is everything | Evaluate
Accord entre Pierre Fabre et Puma Biotechnology
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies
